Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Immunex/Genentech Enbrel Manufacturing Deal Will Expand Capacity In 2004

  • News

Executive Summary

Genentech will be a second contract manufacturer for Immunex' Enbrel under an agreement between the two companies announced April 15

You may also be interested in...



Orencia Marketing Likely To Focus On Broader Mechanism Of Action

Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim

Orencia Marketing Likely To Focus On Broader Mechanism Of Action

Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim

Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready

Genentech will not be reimbursed by Amgen for certain Enbrel manufacturing investments because Genentech's contract production line will not be ready on time, the company disclosed in its 2003 110-K filing
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet
Tags:
UsernamePublicRestriction

Register

PS039709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By